ACE and Alzheimer disease: Several studies on AD transgenic mice revealed no significant differences in cerebral Aβ levels with ACE1 inhibitors; in particular, CD-1 mice injected with enalaprilat did not alter Aβ40 and Aβ42 levels [38–41].